Found: 6
Select item for more details and to access through your institution.
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 6, p. 1235, doi. 10.1007/s40121-024-00972-9
- By:
- Publication type:
- Article
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 745, doi. 10.1007/s40121-024-00944-z
- By:
- Publication type:
- Article
Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 3, p. 1, doi. 10.1093/ofid/ofae097
- By:
- Publication type:
- Article
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile.
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 1, p. 207, doi. 10.1007/s40121-023-00904-z
- By:
- Publication type:
- Article
OP78 Cost-effectiveness Of A 20-valent Pneumococcal Conjugate Vaccine To Directly Protect Adults Against Pneumococcal Disease In England.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, p. S20, doi. 10.1017/S0266462323000983
- By:
- Publication type:
- Article
Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 4, p. 2179, doi. 10.1007/s00520-020-05715-3
- By:
- Publication type:
- Article